Influence of CCR2 and CCR5 receptor genetic variants on HIV-1 infection and disease progression.

被引：0
|
作者：
Smith, MW
Dean, M
Carrington, M
Winkler, C
Huttley, GA
Lomb, DA
Goedert, JJ
O'Brien, TR
Jacobson, LP
Kaslow, R
Buchbinder, S
Vittinghoff, E
Vlahov, D
Hoots, K
Hilgartner, MW
O'Brien, SJ
机构：
[1] NCI, Frederick Canc Res & Dev Ctr, IRSP, SAIC Frederick, Frederick, MD USA
[2] NCI, Lab Genom Divers, Frederick, MD 21701 USA
[3] NCI, Viral Epidemiol Branch, Bethesda, MD 20892 USA
[4] Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21218 USA
[5] Univ Alabama, Dept Epidemiol, Birmingham, AL USA
[6] San Francisco City Clin, Dept Publ Hlth, San Francisco, CA USA
[7] Univ Texas, Sch Med, Dept Pediat, Houston, TX USA
[8] Univ Texas, Sch Med, Dept Internal Med, Houston, TX USA
[9] Cornell Univ, Med Ctr, New York Hosp, Div Pediat Hematol & Oncol, New York, NY 10021 USA
来源：
AMERICAN JOURNAL OF HUMAN GENETICS | 1997年 / 61卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
232
引用
收藏
页码：A45 / A45
页数：1
相关论文
共 50 条
  • [41] How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection
    van Lunzen, Jan
    [J]. EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (09) : 435 - 440
  • [42] CCR5 inhibitors in HIV-1 therapy
    Dorr, Patrick
    Perros, Manos
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (11) : 1345 - 1361
  • [43] CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children
    Misrahi, M
    Teglas, JP
    N'Go, N
    Burgard, M
    Mayaux, MJ
    Rouzioux, C
    Delfraissy, JF
    Blanche, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (04): : 277 - 280
  • [44] Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands
    Ketas, Thomas J.
    Kuhmann, Shawn E.
    Palmer, Ashley
    Zurita, Juan
    He, Weijing
    Ahuja, Sunil K.
    Klasse, Per Johan
    Moore, John P.
    [J]. VIROLOGY, 2007, 364 (02) : 281 - 290
  • [45] Prevalence of CCR5 and CCR2 HIV-coreceptor gene polymorphisms in Belgium
    Struyf, F
    Thoelen, I
    Charlier, N
    Keyaerts, E
    Van der Donck, I
    Wuu, J
    Van Ranst, M
    [J]. HUMAN HEREDITY, 2000, 50 (05) : 304 - 307
  • [46] Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression
    Srinivas Mummidi
    Seema S. Ahuja
    Enrique Gonalez
    Stephanie A. Anderson
    Elvin N. Santiago
    Kevin T. Stephan
    Fiona E. Craig
    Peter O'Connell
    Victor Tryon
    Robert A. Clark
    Matthew J. Dolan
    Sunil K. Ahuja
    [J]. Nature Medicine, 1998, 4 : 786 - 793
  • [47] Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression
    Mummidi, S
    Ahuja, SS
    Gonzalez, E
    Anderson, SA
    Santiago, EN
    Stephan, KT
    Craig, FE
    O'Connell, P
    Tryon, V
    Clark, RA
    Dolan, MJ
    Ahuja, SK
    [J]. NATURE MEDICINE, 1998, 4 (07) : 786 - 793
  • [48] Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5
    Ogilvie, P
    Bardi, G
    Clark-Lewis, I
    Baggiolini, M
    Uguccioni, M
    [J]. BLOOD, 2001, 97 (07) : 1920 - 1924
  • [49] Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc
    Latinovic, Olga
    Kuruppu, Janaki
    Davis, Charles
    Le, Nhut
    Heredia, Alonso
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1497 - 1510
  • [50] CCR5 and CCR2 gene polymorphisms in hypertensive patients
    Mettimano, M
    Specchia, ML
    Ianni, A
    Arzani, D
    Ricciardi, G
    Savi, L
    Romano-Spica, V
    [J]. BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2003, 60 (01) : 19 - 21
12345